Abstract Simple and sensitive Liquid ChromatographyTandem Mass Spectrometry (LCMS/MS) method was developed and validated, then was implicated on hypertensive human subjects to study drug interaction of atorvastatin (ATVS) and Olmesartan (OLM) on status of Angiotensin-II (ANG-II). The ANG-II in plasma was extracted with 5 mL methanol containing 5 % formic acid through C 18 (cartridges) liquid-liquid extraction, dried and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water. The chromatographic separation of ANG-II with a Agilent technology 6410 Triple quadrupole was carried multiple reaction monitoring scan mode with a Agilent 1290 Infinity LC system for UHPLC. The sample were separated on a (Thermo Scientific) Hy-Purity advance (50 9 4.6 mm, 5 lm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min, performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min. The developed method was validated for specificity, accuracy, precision, stability, linearity, sensitivity and recovery. The method was linear between peak area ratio of standard and internal standard over the range of 50-800 ng/mL. The method was successfully applied for the drug interaction study revealed levels of ANG-II were significantly higher in ATV-S ? OLM treatment condition as compared to individual treatment of OLM. This reflects the reason of low effectiveness of ATVS ? OLM in combination instead of synergistic activity.
Introduction
Angiotensin II (ANG-II) is the biologically active product of the renin-ANG system [1, 2] . The octapeptide ANG-II (molecular weight 1,046) is the strongest physiological vasoconstrictor known. From a large protein precursor (pre-proangiotensinogen) synthesized in the liver it is liberated in a series of proteolytic steps catalyzed by enzymes from various tissues [1] [2] [3] . ANG-II is very short-lived in the plasma: Once generated from ANG-I, it is degraded further into physiologically inactive peptides by various plasma peptidases, at a plasma half life of less than a minute [4] . Olmesartan (OLM) medoxomil is the latest ANG-II receptor blocker approved for use in US. Potential advantages of this drug include once-daily dosing, an absence of significant adverse reactions, a well-tolerated side-effect profile, and a cost-effective. OLM medoxomil is currently being used as an alternative therapeutic antihypertension agent for patients intolerant of ANG-converting enzyme inhibitors [5] . Peak plasma concentrations of OLM occurred 1-3 h after administration, after which concentrations decreased quickly. The elimination half-life was 10-15 h. Bioavailability increased proportionally with dose, after single and multiple daily oral doses, over the therapeutic dose range, up to 40-80 mg daily [6] .
The OLM peak concentration in blood determines the aldosterone (ALD) secretion as well as concentration of ANG-II too, for an instantaneous time interval, which later converted into ANG-III and ALD. So, the tracing of ANG-II high peak level with its control study is very crucial at that stage.
Virtually all of the biological actions of the principle effector peptide ANG-II have been attributed to an action at the type 1 (AT1) ANG receptor. Evidence has now accumulated that the AT2 receptor opposes functions mediated by the AT1 receptor. Whereas the AT1 receptor stimulates cell proliferation, the AT2 receptor inhibits proliferation and promotes cell differentiation [7] [8] [9] [10] [11] [12] . Until now, there have been many reports of peptides with respect to analysis of drugs in plasma using column switching techniques [13] [14] [15] . Analysis of ANG peptides has been performed using HPLC combined with radioimmunoassay [16] [17] [18] [19] . Liquid chromatography-mass spectrometry (LC-MS) features high selectively and high sensitivity. LC-MS is a useful tool for biological analysis and is widely used for identification and quantification of proteins and peptides. Usually, LC-MS is used to provide initial identification based on molecular weight, LC-MS/MS provide further confirmation via structural specific fragmentation. The combination of LC-MS and LC-MS/MS analysis allows sensitive and unambiguous analysis of peptides in complex sample matrices. 
Method

Chemicals and Reagents
Chromatographic Conditions
The sample were separated on a (Thermo Scientific) HyPurity advance (50 9 4.6 mm, 5 lm) using Mobile Phase A: 16 % acetonitrile in 0.1 % formic acid in water and Mobile Phase B: 0.1 % formic acid in methanol at a flow rate of 0.3 mL/min. All HPLC separations were performed at ambient temperature. The mobile phase gradient of 16 % acetonitrile in water was linearly increased to 38 % acetonitrile over 10 min and subsequently the mobile-phase was increased to 100 % acetonitrile over 15 min (Table 1) .
MS/MS Conditions
The positive ion ESI mass spectrometric conditions were: capillary voltage 6 kV, cone voltage 20-25 V, desolvation temperature 350°C, desolvation gas flow 600 L/h and the source temperature is 120°C. LC-MS/MS was performed with MRM of transition of precursor ion ? product ion m/z 349.6 ? 255.1 and 523.8 ? 263.2. The collision energies were set at 20 eV.
Preparation of Calibration Standards and Quality Control Samples
The calibration standards were prepared by spiking human plasma with standard ANG-II with corresponding IS, ANG-II (ANG-III) to obtain resultant concentrations of 5, 10, 25, 50, 100, 200 ng/mL. The developed method was validated using three different quality control (QC) samples by spiking ANG-II in human plasma at 5, 50 and 200 ng/mL to represent low QC (LQC), middle QC (MQC) and high QC (HQC), respectively.
Sample Extraction Procedure
From the separated plasma, 250 lL of sample was taken and 500 lL of 0.5 % formic acid was added to it. Cartridges (Rida, C 18 ) were used, the cartridges was pre-conditioned Step 2 Up to 38 % 62 5-10 0.3
Step 3 Up to 100 % 0 10-15 0.3
Ind J Clin Biochem (July-Sept 2015) 30(3):334-344 335 with 5 mL methanol and 5 mL of Milli Q water. The sample was then loaded into the cartridge, thereafter the cartridge was washed with 5 mL of water. Finally, the sample was eluted with 5 mL methanol containing 5 % formic acid. Then the sample was made evaporate up to dryness under nitrogen and reconstituted with 1 mL of 16 % acetonitrile in 0.1 % formic acid in water and was transferred to a sample vial for LCMS and LCMS/MS analysis.
Method Validation
Selectivity and Specificity ANG-II is an endogenous compound present in humans, as a part of specificity studies plasma devoid of ANG-II was obtained from patients suffering from severe hypotensive disorders which are having no circulating ANG-II in them. The obtained plasma sample was processed by the liquid-liquid extraction procedure. The samples were chromatographed to determine to which extent endogenous plasma components may contribute to the peak interference at retention times of ANG-II. Also the eqi-volume of spiked plasma of standard ANG-III and ANG-III (IS) represent the exact location of peaks and ratio of extracted ANG-III from plasma with this methodology.
Linearity
Calibration curves were prepared by adding a known amount of ANG-II as well as ANG-III, IS (5, 10, 25, 50, 100 and 200 ng/mL) to 0.5 mL of blank plasma. The samples were extracted as described previously. The standard curves were constructed by plotting the peak area ratio of ANG-II concentration and of ANG-III (IS) upon X and Y-axis concentration ranges. Linearity was assessed by observing the values of coefficient of correlation (r 2 ) of linearity plots, nearness of values near to 1 suggested linearity of responses. Also, the linearity of each standard curve was confirmed by plotting the peak area of ANG-II. The unknown sample concentrations were calculated from the weighted (1/x 2 ) linear regression analysis of the standard curve.
Precision and Accuracy
Inter and intra-day precision studies were done by injecting QC dilutions (5, 50 and 200 ng/mL) as described earlier (n = 12) in developed chromatographic method. Peak areas were calculated for %RSD values.
Extraction Recovery
To calculate recovery of the extraction procedure, 12 replicates of QC samples of ANG-II (5, 50 and 200 ng/mL) were extracted and analyzed. The peak area was compared with the same concentrations of unextracted standards of ANG-II reconstituted in methanol.
Stability
In bench-top stability, 12 replicates of LQC and HQCs of ANG-II (5 and 200 ng/mL) were analyzed at 0 and 6 h at room temperature and the deviation was calculated. In freeze-thaw stability, 12 replicates of LQC and HQC samples of ALD were prepared, frozen at -20°C and analyzed after two and three freeze-thaw cycles. Longterm stability was examined for 14 days by taking 12 replicates of HQC and LQC samples. The mean concentration was taken into consideration, which was compared with zero-day sample concentration.
LOD and LOQ
The limits of detection (LOD) and limits of quantification (LOQ) were determined by injecting progressively low concentrations of the standard solution under the chromatographic conditions. LOD and LOQ were calculated directly from the calibration plot. LOD and LOQ were calculated as 1.3 and 10 r/S, respectively, where r is the standard deviation (SD) of intercept and S is the slope of the calibration plot. The LOD was defined as a signal-tonoise (S/N) ratio of 3:1 and the LOQ was defined as an S/N ratio of 10.
Study Design
The study on human volunteers was carried under approval of ethics committee ''HURIP Independent Bioethics'', Ibrahimpur Road, Kolkata, India. The study was performed along with patients consent and under supervision of Doctor. Twelve hypertensive patients aged between 21 and 30 years, non-infected, not under any antibiotics, steroid and other medicines therapy for a month, except specific cardiovascular drug provided by experts for this study. The patients were routinely supervised and also prescribed with single category of medicines, i.e., OLM and atorvastatin (ATVS), according to their therapeutic regimens.
The collection of blood plasma was basically done three times per individual for 7-14 days in first stage without any drug administration. Secondly, along with combination of OLM ? ATVS and thirdly with only single hypertensive drug, i.e., OLM. First stage was for 1 week in which the patients were devoid of any antihypertensive drugs. The patients were evaluated for demography and measurement of blood pressure (BP) followed by withdrawal of blood to quantify the levels of ANG-II.
Results and Discussion
Method Validation
Selectivity and Specificity (Matrix Effect)
Blank plasma obtained from patients suffering from severe hypotension was used for studies. The plasma was used to mark any endogenous interference. A representative chromatogram of the plasma blank is shown in Fig. 1 . No additional peaks of endogenous substances were observed. Figure 2 shows the chromatograms of calibration standard containing ANG-II spiked in plasma with ANG-III (IS).
Linearity
Linear calibration curves (Fig. 4) with correlation coefficients near to 0.99806448 were obtained over the concentration range of ANG-II (5, 10, 25, 50, 100 and 200 ng/mL) to 0.5 mL of blank plasma. The coefficient of regression, i.e., r 2 = 0.998 was obtained indicating linearity of results and an excellent correlation between peak area ratio for each concentration of ANG-II. The chromatograms of peaks area of ANG-II and ANG-III on concentration 5, 10, 25, 50, 100 and 200 ng/mL (Fig. 3) as comparative peak area ratio. The plasma spiked ANG-II (std) and ANG-III (IS) calibrated curve (Fig. 5) represents regression line linearity equation of y = 0.985x ? 0.861 and coefficient of regression r 2 = 0.999, which is also an excellent correlation between area ratio of ANG-II (std) and ANG-III (IS) linearity.
Accuracy and Precision
Method performance was evaluated as accuracy and precision as shown in the Tables 2 and 3, determined by 12 replicate analyses for ANG-II at three concentration levels, i.e., LQC (5 ng/mL), MQC (50 ng/mL) and HQC (200 ng/ mL), each on the same analytical run. Inter-assay precision and accuracy were calculated after repeated analysis in three different analytical runs. Results concluded the repeatability of the method, including both sample processing and chromatographic measurement. Recovery results were subjected statistically analysis and %RSD were recorded. The %RSD is a ratio of SD to mean in percent. %RSD values were small indicating good accuracy of results. Inter-day and intra-day results also were good as the %RSD values were low.
Extraction Recovery
Extraction recovery of ANG-II was determined by comparing peak areas obtained from extracted plasma samples with those found by extracting blank matrices through the extraction procedure and spiking with a known amount of ANG-II. The results showed that the mean extraction recovery of ANG-II was [85 % at three (Table 4) .
Averaged for 12 measurements at each concentration level ðn ¼ 12Þ; % Recovery ¼ ðresponse of extracted spikeÞ= ðresponse of post-extracted spikeÞ Â 100:
Stability
In bench-top stability, six replicates of LQC and HQCs of ANG-II (5 and 200 ng/mL) analyzed at 0 and 6 h at room temperature resulted in recovery in acceptable ranges, at 0 h the recovery of ANG-II from plasma was 95.6 % for LQC and 101.2 % for HQC, whereas after 6 h the extraction recovery of ANG-II was 92.5 % for LQC and 98.2 % for HQC. The recovery of ANG-II for freezethaw stability studies was found to be within the limits as per the guidelines. For LQC sample mean recovery for second and third freeze-thaw stability cycle were 96.9 and 94.8 %, respectively, for HQC samples the mean recoveries for second and third freeze-thaw stability cycle were 102.3 and 101.6 %, respectively which were well inside the acceptable ranges as per the guidelines (i.e., ±15 %). Long term stability results for extraction recovery of LQC and HQC samples resulted in acceptable recoveries concluding the method suitable to stability studies for long periods.
Sensitivity Studies (LOD and LOQ)
The method was confirmed for sensitivity by estimating LOD and LOQ. The method exhibited excellent sensitivity by demonstrating LOD of 0.16 ng/mL and LOQ of 0.520 ng/mL.
Application of the Analytical Method in Pharmacokinetic Studies
The developed LCMS/MS method for quantification of ANG-II in plasma was applied for the drug interaction study in hypertensive patients under the antihypertensive drug therapy. Blood was collected after dosing thereafter immediately the BP was observed in lying posture for same individual patient in three stages and similarly with rest of the volunteer (patients). Table 5 shows that there were significant reduction (P \ 0.001) in the BP of volunteers with OLM when compared to without treatment stage. The plasma concentration of ANG-II was calculated in the hypertensive human volunteers by using given developed method. There were significant decrease (P \ 0.001) in the level of ANG-II in ATVS ? OLM treated stage when compared to the without treatment stage in human volunteer. Whereas the concentration of ANG-II in the OLM treated stage was lower than the detection limit as shown in the Table 6 .
Conclusion
Present study was undertaken to develop a sensitive method for quantification of ANG-II in human plasma. The developed LCMS/MS method was validated in accordance to guidelines and confirmed to be specific, selective, linear, accurate, precise and sensitive. The method exhibited acceptable recovery from spiked plasma samples also the method was proved to be sensitive demonstrating excellent LOD and LOQ levels of 0.16 and 0.520 ng/Ml, respectively.
The validated sensitive method was applied for pharmacokinetic studies to quantify the levels of ANG-II in human volunteers under therapy of ATVS, OLM and combinations of both. The study concluded that the concentration of ANG-II in human volunteers treated with ATVS ? OLM was higher than the OLM treated hypertensive human volunteer also the demographic characters revealed decrease in BP of OLM treated patients as compared to ATVS ? OLM treated ones. Thus, the present study concludes failure of combination therapy for fulfilling the objective of synergistic activity in treating ANG-II mediated BP as cardiovascular therapeutics, rather than the individual drug treatment (Fig. 6) . Mean ± SEM 4.4917 ± 0.06519 10.5715 ± 0.06820*** 17.61363 ± 0.10812*** 
